MedTrace Logo

"NORPLASMA" Covid-19 Convalescent Plasma Treatment Monitoring Study

NCT04463823 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2023-12-05

No results posted yet for this study

Summary

NORPLASMA COVID-19 includes both the production of convalescent plasma from approved blood donors who have recovered from covid-19 (coronavirus disease 2019), and clinical studies to evaluate efficacy and safety of the treatment, as recommended by European health authorities. Patients who receive convalescent plasma in a clinical setting will be invited to participate in the monitoring study NORPLASMA MONITOR, where clinical data about safety and effect on clinical parameters including virus load and recovery time will be collected and compared to european patients in a common database for the European countries. The treated patients can be compared to a historical control group.

Conditions

Sponsors & Collaborators

  • St. Olavs Hospital

    collaborator OTHER

  • Sykehuset Telemark

    collaborator OTHER_GOV

  • Sykehuset Ostfold

    collaborator OTHER

  • University Hospital, Akershus

    collaborator OTHER

  • Sorlandet Hospital HF

    collaborator OTHER_GOV

  • Helse Fonna

    collaborator OTHER

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Lise Sofie Haug Nissen-Meyer, Ph.D. · Oslo University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-06
Primary Completion
2024-05-31
Completion
2025-05-31

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04463823 on ClinicalTrials.gov